ARTICLE | Clinical News
IL-4 Fusion Toxin regulatory update
October 18, 1999 7:00 AM UTC
The FDA granted fast track designation for NBIX's NBI-3001 fusion protein that combines interleukin-4 (IL-4) with Pseudomonas exotoxin. The compound is in Phase II testing to treat glioblastoma. ...